Multivariable analysis on the relative risk of major thrombosis among 1063 ET patients11
| . | 8.0-11.0 × 109/L white blood cell count* (n = 432) . | More than 11.0 × 109/L white blood cell count* (n = 220) . | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | |
| Major thrombosis | ||||
| (1) Unadjusted | 1.3 (0.8-1.9) | .3 | 1.7 (1.0-2.7) | .04 |
| (2) Variables adjusted | 1.4 (0.9-2.1) | .2 | 1.8 (1.1-2.9) | .02 |
| (3) +JAK2V617F adjusted | 1.5 (0.9-2.5) | .1 | 2.0 (1.1-3.6) | .02 |
| . | 8.0-11.0 × 109/L white blood cell count* (n = 432) . | More than 11.0 × 109/L white blood cell count* (n = 220) . | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) . | P . | Hazard ratio (95% CI) . | P . | |
| Major thrombosis | ||||
| (1) Unadjusted | 1.3 (0.8-1.9) | .3 | 1.7 (1.0-2.7) | .04 |
| (2) Variables adjusted | 1.4 (0.9-2.1) | .2 | 1.8 (1.1-2.9) | .02 |
| (3) +JAK2V617F adjusted | 1.5 (0.9-2.5) | .1 | 2.0 (1.1-3.6) | .02 |
Model 1: platelet count (3 categories) or white blood cell count (3 categories).
Model 2: model 1 plus center (3 categories), sex (2 categories), standard risk factors: age 60 years or older and/or previous thrombotic event (yes/no), hemoglobin at diagnosis (2 categories, median value used as cutoff), white blood cell count or platelet count at diagnosis (2 categories, median value used as cutoff), antiplatelet use (yes/no), chemotherapy use (yes/no).
Model 3: model 2 plus JAK2V617F status (yes/no).
Reference categories: white blood cell count lower than 8 ×109/L. Cutoffs arbitrarily defined.